Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Formulations comprising heterocyclic protein kinase inhibitors

Formulations comprising heterocyclic protein kinase inhibitors

US Patent 11471456 · Granted Oct 18, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Antimitotic amides for the treatment of cancer and proliferative disorders2025
Alvocidib prodrugs having increased bioavailability2025
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer2024
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer2024
ALK-5 inhibitors and uses thereof2023
ALK-5 inhibitors and uses thereof2023
Compositions comprising PKM2 modulators and methods of treatment using the same2023
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof2022
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof2022
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer2022
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer2022
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the2022